Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual Meeting
April 27 2022 - 7:30AM
Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage
biopharmaceutical company focused on developing transformative
medicines for the treatment of ocular diseases, today announced a
poster presentation of preclinical data for GB-401 in primary
open-angle glaucoma (POAG) at the upcoming Association for Research
in Vision and Ophthalmology (ARVO) Annual Meeting, to be held at
the Colorado Convention Center in Denver from May 1-4, 2022.
Information is listed below and available on the ARVO
website.
In Vitro and In Vivo Characterizations of GB-401, a
Sustained-Release Intravitreal Implant Containing a Beta-Adrenergic
Antagonist Prodrug for POAGPresenter: Yun Yu, PhD,
Associate Director R&D, Graybug Vision Poster Session: Drug
Delivery Date and Time: Wednesday May 4, 2022; 12:30 – 2:30 PM MT
(2:30 – 4:30 PM ET)Location: Poster Hall - F0151
A copy of the poster will be made available in the Investors and
Media section of the company’s website – in the Medical Events and
Publications tab – at the same time.
About Graybug
Graybug is a clinical-stage biopharmaceutical company focused on
developing transformative medicines for ocular diseases. The
company’s diversified portfolio is designed to treat
vision-threatening diseases of the retina, optic nerve, and cornea,
by either maintaining effective drug levels in ocular tissues for
long periods of time, using innovative technologies, such as
injectable sustained-release formulations, or by curing diseases
with gene therapies. Graybug’s most advanced drug candidate,
GB-102 is a microparticle formulation of a
pan-VEGF inhibitor, sunitinib, for the treatment of wet age-related
macular degeneration designed for a twice-per-year intravitreal
injection. GB-102 has the potential to also benefit patients with
diabetic retinopathy. GB-401 is a first-in-class
implant formulation containing a novel prodrug of timolol for the
treatment of primary open-angle glaucoma (POAG) designed for a
twice-per-year intravitreal injection with a proprietary
applicator. GB-501 is an adeno-associated virus
(AAV) gene therapy with Orphan Drug Designation (ODD) and Rare
Pediatric Disease Designation (RPDD) to treat corneal clouding
caused by mucopolysaccharidosis type 1 (MPS1), a lysosomal storage
disorder. GB-601 is being developed as a
long-acting formulation of a novel cGMP analog to address
hereditary retinal diseases like retinitis pigmentosa, a group of
genetic disorders that involve a loss of cells in the retina.
GB-701 is being developed as a long-acting
formulation of a potent factor B inhibitor targeting the complement
cascade which plays a role in AMD. Founded in 2011 based on
technology licensed from the Johns Hopkins University School of
Medicine, Graybug has offices in Redwood City, California and in
Baltimore, Maryland. For more information, please visit
www.graybug.vision.
Investor
ContactIR@graybug.vision(650) 487-2409 |
Media
Contactmedia@graybug.vision(404) 384-0067 |
Graybug Vision (NASDAQ:GRAY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Graybug Vision (NASDAQ:GRAY)
Historical Stock Chart
From Jul 2023 to Jul 2024